Hikma Pharma to acquire stake in UnimarkIllustrative image – not actual.

Jordan headquartered Hikma Pharmaceuticals Plc is likely to acquire a minority interest in Unimark Remedies, a maker of active pharmaceutical ingredients and API intermediates.

The deal is likely to be valued at about $33.3 million (approx Rs 148.5 crore). Hikma will source pharmaceutical ingredients from Unimark, while Unimark is likely to use the marketing arm of Hikma in the US for future distribution of Unimark's branded generic drugs.

Unimark operates three API facilities, two in Gujarat (Vapi and Bavla) and one at Khopoli in Maharashtra.

← All latest storiesBack to top →